Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2017 Dec 13

PMID 29229764

Citations 7

Authors

H Terence Cook

Matthew C Pickering

Affiliations

Soon will be listed here.

Citing Articles

Short-term renal and patient outcomes of primary immunoglobulin-associated mesangiocapillary glomerulonephritis: Insights from a developing country.

Elahi T, Ahmed S, Mubarak M World J Nephrol. 2024; 13(4):98969.

PMID: 39723356 PMC: 11572649. DOI: 10.5527/wjn.v13.i4.98969.

C3G and Ig-MPGN-treatment standard.

Noris M, Remuzzi G Nephrol Dial Transplant. 2023; 39(2):202-214.

PMID: 37604793 PMC: 10828209. DOI: 10.1093/ndt/gfad182.

Diagnostic and Prognostic Comparison of Immune-Complex-Mediated Membranoproliferative Glomerulonephritis and C3 Glomerulopathy.

Kovala M, Seppala M, Raisanen-Sokolowski A, Meri S, Honkanen E, Kaartinen K Cells. 2023; 12(5).

PMID: 36899849 PMC: 10000503. DOI: 10.3390/cells12050712.

Kidney diseases.

Daina E, Cortinovis M, Remuzzi G Immunol Rev. 2022; 313(1):239-261.

PMID: 36369988 PMC: 10099622. DOI: 10.1111/imr.13167.

Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis.

Garam N, Prohaszka Z, Szilagyi A, Aigner C, Schmidt A, Gaggl M Clin Kidney J. 2020; 13(2):225-234.

PMID: 32296528 PMC: 7147314. DOI: 10.1093/ckj/sfz073.

References

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E . Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016; 71:131-142. DOI: 10.1016/j.molimm.2016.01.010. View

Hou J, Markowitz G, Bomback A, Appel G, Herlitz L, Stokes M . Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 2013; 85(2):450-6. DOI: 10.1038/ki.2013.340. View

Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B . Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet. 2006; 44(3):193-9. PMC: 2598029. DOI: 10.1136/jmg.2006.045328. View

Gale D, Goicoechea de Jorge E, Cook H, Martinez-Barricarte R, Hadjisavvas A, McLean A . Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet. 2010; 376(9743):794-801. PMC: 2935536. DOI: 10.1016/S0140-6736(10)60670-8. View

Fakhouri F, Fremeaux-Bacchi V, Noel L, Cook H, Pickering M . C3 glomerulopathy: a new classification. Nat Rev Nephrol. 2010; 6(8):494-9. DOI: 10.1038/nrneph.2010.85. View

Athanasiou Y, Voskarides K, Gale D, Damianou L, Patsias C, Zavros M . Familial C3 glomerulopathy associated with CFHR5 mutations: clinical characteristics of 91 patients in 16 pedigrees. Clin J Am Soc Nephrol. 2011; 6(6):1436-46. PMC: 3109942. DOI: 10.2215/CJN.09541010. View

Fervenza F, Sethi S, Glassock R . Idiopathic membranoproliferative glomerulonephritis: does it exist?. Nephrol Dial Transplant. 2012; 27(12):4288-94. DOI: 10.1093/ndt/gfs288. View

Servais A, Noel L, Roumenina L, le Quintrec M, Ngo S, Dragon-Durey M . Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012; 82(4):454-64. DOI: 10.1038/ki.2012.63. View

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011; 31(4):341-8. DOI: 10.1016/j.semnephrol.2011.06.005. View

10.

Berger J, Galle P . [DENSE DEPOSITS WITHIN THE BASAL MEMBRANES OF THE KIDNEY. OPTICAL AND ELECTRON MICROSCOPIC STUDY]. Presse Med (1893). 1963; 71:2351-4. View

11.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C . Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol. 2017; 29(1):283-294. PMC: 5748907. DOI: 10.1681/ASN.2017030258. View